Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

12
895
0
27

Year Published

2015
2015
2020
2020

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 1,302 publications
(934 citation statements)
references
References 4 publications
12
895
0
27
Order By: Relevance
“…The prognosis of astrocytoma differs according to features such as age, disease stage, and histological type. GBM is the most malignant astrocytoma, with a median overall survival (OS) of approximately 12 months and a 5‐year OS of 4.8%‐5.4%,1, 2, 3 while patients suffering from anaplastic astrocytoma have a median OS of 38 months and a 5‐year OS of 25.9%‐41.1% 1, 4. A deeper understanding of the prognostic factors of GBM may provide new ideas for the prevention and management of this disease.…”
Section: Introductionmentioning
confidence: 99%
“…The prognosis of astrocytoma differs according to features such as age, disease stage, and histological type. GBM is the most malignant astrocytoma, with a median overall survival (OS) of approximately 12 months and a 5‐year OS of 4.8%‐5.4%,1, 2, 3 while patients suffering from anaplastic astrocytoma have a median OS of 38 months and a 5‐year OS of 25.9%‐41.1% 1, 4. A deeper understanding of the prognostic factors of GBM may provide new ideas for the prevention and management of this disease.…”
Section: Introductionmentioning
confidence: 99%
“…Glioblastoma multiforme (GBM) is the most common and lethal cancer of the brain, with approximately 10,000 newly diagnosed cases each year in the United States 1. Despite recent advances in understanding of its pathogenesis, GBM remains incurable with standard treatment options contributing little to survival time.…”
Section: Introductionmentioning
confidence: 99%
“…Despite recent advances in understanding of its pathogenesis, GBM remains incurable with standard treatment options contributing little to survival time. Currently, GBM has a 5‐year survival rate of only 10% and a median survival time of 15 months following treatment 1, 2. Contributing to its poor prognosis are numerous therapeutic challenges including aggressive growth rates, tumor heterogeneity, drug resistance, and obstacles to drug delivery such as the blood–brain barrier.…”
Section: Introductionmentioning
confidence: 99%
“…For lower grades, the survival rate is between 4 and 15 years. Malignant meningiomas have a 5 years survival of 65% (Ostrom et al., 2014). …”
Section: Introductionmentioning
confidence: 99%